CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

February 1, 2029

Study Completion Date

May 1, 2029

Conditions
Chemotherapy-Induced Peripheral Neuropathy
Interventions
DRUG

CBG/CBD Oil

Participants will receive a commercially available high CBG/CBD hemp extract oil that also contains small amounts of cannabichromene (CBC). The product is formulated as a sublingual oil and administered twice daily. Participants will take 0.5 mL of the oil sublingually twice daily during the first week, followed by 1 mL sublingually twice daily for the remaining 11 weeks. The oil has a defined and independently verified cannabinoid and terpene profile and is marketed as a dietary supplement.

Trial Locations (1)

17033

Penn State Cancer Institute, Hershey

All Listed Sponsors
lead

Milton S. Hershey Medical Center

OTHER